Loading…
Fulcrum Therapeutics, Inc. is projected to rise to $3.68 by 2027, a +5% move from its current price of $3.50. FULC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $3.38 | $3.50 | $3.63 | +0.01% |
| Jul 13 | $3.33 | $3.50 | $3.68 | +0.02% |
| Jul 14 | $3.29 | $3.50 | $3.72 | +0.04% |
| Jul 15 | $3.26 | $3.50 | $3.76 | +0.05% |
| Jul 16 | $3.24 | $3.50 | $3.79 | +0.06% |
| Jul 17 | $3.21 | $3.50 | $3.82 | +0.07% |
| Jul 18 | $3.19 | $3.50 | $3.84 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.19 | $3.50 | $3.84 | +0.08% |
| Week 2 | $3.07 | $3.51 | $4.00 | +0.17% |
| Week 3 | $2.99 | $3.51 | $4.12 | +0.25% |
| Week 4 | $2.92 | $3.51 | $4.23 | +0.34% |
| Week 5 | $2.86 | $3.51 | $4.33 | +0.42% |
| Week 6 | $2.80 | $3.52 | $4.42 | +0.50% |
| Week 7 | $2.75 | $3.52 | $4.50 | +0.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined diseases in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
The company also discovers programs for the treatment of Diamond-Blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, and fibrotic disorders. Fulcrum was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. It has a license agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize.
Fulcrum Therapeutics, Inc. currently trades at $3.50 per share and has a market cap of $233.22M, with a rank of 3688. The current price and market position place it within a smaller-cap segment of the healthcare landscape.
A major floor 78.9% below — a decisive break under it would weaken the trend.
The nearest floor, 10.3% below — buyers have tended to step in here.
The nearest ceiling, 97.7% above — a clean break opens room to run.
A major ceiling 138.6% above — clearing it would confirm fresh momentum.
Key FULC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FULC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.66 | Sell | $3.63 | Sell |
| MA 10 | $3.70 | Sell | $3.67 | Sell |
| MA 20 | $3.66 | Sell | $3.87 | Sell |
| MA 50 | $5.08 | Sell | $4.88 | Sell |
| MA 100 | $6.56 | Sell | $6.15 | Sell |
| MA 200 | $8.35 | Sell | $7.03 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.80 | Neutral |
| Stoch RSI (14) | 26.83 | Neutral |
| CCI (20) | -94.89 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.10 | Buy |
| ROC (12) | -9.09 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.52 | Sell |
| Awesome (5,34) | -0.57 | Sell |
| Ultimate (7,14,28) | 37.27 | Neutral |
| Momentum (10) | -0.11 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 3.61 | Sell |
| ADX (14) | 29.46 | Sell |
| ATR (14) | 0.15 | Info |
The forecast indicates a neutral near-term setup, with RSI at 30 and a 30-day sentiment labeled NEUTRAL. The 30-day range spans from $2.78 to $4.41, indicating recent trading within that window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.14 | $3.50 | $4.53 | 0% | Neutral | |
| $2.85 | $3.68 | $5.07 | +5% | Neutral | |
| $3.65 | $4.89 | $7.04 | +40% | Bullish | |
| $4.12 | $5.69 | $8.49 | +62% | Bullish | |
| $4.35 | $6.17 | $9.50 | +76% | Bullish | |
| $4.62 | $6.72 | $10.61 | +92% | Bullish | |
| $4.29 | $6.40 | $10.34 | +83% | Bullish | |
| $4.58 | $6.98 | $11.52 | +100% | Bullish | |
| $4.86 | $7.57 | $12.72 | +116% | Bullish | |
| $5.39 | $8.57 | $14.66 | +145% | Bullish | |
| $6.50 | $11.36 | $20.91 | +225% | Bullish | |
| $12.26 | $25.39 | $51.92 | +625% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.14 | $3.50 | $4.28 | +0.00% |
| August 2026 | $2.94 | $3.50 | $4.29 | -0.08% |
| September 2026 | $2.95 | $3.54 | $4.40 | +1.18% |
| October 2026 | $3.05 | $3.69 | $4.65 | +4.37% |
| November 2026 | $3.00 | $3.65 | $4.64 | -1.22% |
| December 2026 | $2.88 | $3.53 | $4.53 | -3.32% |
Click any year to see its month-by-month FULC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, FULC could reach as high as $4.53, with a base case around $3.50 and support toward $3.14 — roughly 0% from $3.50. A consolidation phase looks the most probable path here.
Expect FULC to range from $2.85 to $5.07 through 2027. The $3.68 average target implies a +5% move from current prices. That is up +5% on the projected 2026 average. Price action looks broadly range-bound.
The FULC price prediction for 2028 points to an average of $4.89 (low $3.65, high $7.04) — a potential gain of +40% on today's $3.50. Buyers look set to stay in control over this stretch.
In 2029, FULC is projected to trade between $4.12 and $8.49, averaging $5.69 — a potential gain of +62% from today's $3.50. That is up +16% on the projected 2028 average. Momentum favours further upside here.
Fulcrum Therapeutics, Inc.'s 2030 outlook centres on $6.17, within a $4.35 to $9.50 range. That is up +9% on the projected 2029 average. That marks a +76% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, FULC could reach as high as $10.61, with a base case around $6.72 and support toward $4.62 — roughly +92% from $3.50. Momentum favours further upside here.
Expect FULC to range from $4.29 to $10.34 through 2032. The $6.40 average target implies a +83% move from current prices. That is -5% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The FULC price prediction for 2033 points to an average of $6.98 (low $4.58, high $11.52) — a potential gain of +100% on today's $3.50. Momentum favours further upside here.
In 2034, FULC is projected to trade between $4.86 and $12.72, averaging $7.57 — a potential gain of +116% from today's $3.50. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Fulcrum Therapeutics, Inc.'s 2035 outlook centres on $8.57, within a $5.39 to $14.66 range. That is up +13% on the projected 2034 average. That marks a +145% change versus current levels. Momentum favours further upside here.
By 2040, FULC could reach as high as $20.91, with a base case around $11.36 and support toward $6.50 — roughly +225% from $3.50. Buyers look set to stay in control over this stretch.
Expect FULC to range from $12.26 to $51.92 through 2050. The $25.39 average target implies a +625% move from current prices. That is up +124% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in FULC today (≈ 285.714286 FULC) could be worth
$7,253.96
+$6,253.96 (+625%) by 2050 · US Dollar
Based on the average projected FULC price of $25.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FULCwould be worth at today's price.
$1,000 invested in FULC on Jul 10, 2025 (≈ 124.843942 FULC) would be worth
$436.95
-$563.05 (-56.3%) today · 0.44× · US Dollar
Based on a FULC entry price of $8.01 vs. today's $3.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.84 | $911.46 | -8.9% |
| 1 month ago | $3.51 | $997.15 | -0.3% |
| 3 months ago | $7.55 | $463.58 | -53.6% |
| 6 months ago | $9.51 | $368.03 | -63.2% |
| 1 year ago | $8.01 | $436.95 | -56.3% |
| All time (5.0y) ago | $9.85 | $355.33 | -64.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FULC forecast.
Our base-case forecast reaches $7.00 around 2034.
Implied market cap at $7.00: $466.43M
The multi-year forecast shows a bullish trend developing into the later years. In 2026 the avg price is $3.50 with a min of $3.14 and a max of $4.53 and ROI of 0% (sentiment NEUTRAL). The outlook strengthens with bullish sentiment from 2028 onward, as the avg price rises to $4.89 in 2028 and $6.17 in 2030 (min $4.35, max $9.50) with ROI 76.4%.
By 2040 the avg price is $11.36 (min $6.50, max $20.91) with ROI 224.6%, and by 2050 the avg price reaches $25.39 (min $12.26, max $51.92) with ROI 625.4%. These figures illustrate considerable upside potential alongside notable uncertainty inherent in long-term estimates.
Tap a question to reveal the answer.
In 2030 the forecast shows an avg price of $6.17, a min of $4.35, and a max of $9.50, with ROI 76.4% and bullish sentiment.
The forecast turns bullish from 2028 onward, with rising average prices and ROI reaching 76.4% by 2030 and 625.4% by 2050, though these are estimates and not guarantees.
Yes. The 2050 max forecast is $51.92, indicating a potential to approach the $50 level within the forecast period.
The current price is $3.50 and the market cap is $233.22M. The stock is ranked 3688.
RSI(14) is 30 and the sentiment is NEUTRAL. The 30-day range is $2.78–$4.41, with SMA50 at $5.08 and SMA200 at $8.35. Support is at $3.14 and resistance at $6.92, with annualized volatility of 70%.
Fulcrum Therapeutics, Inc. Community Discussion
0Share your Fulcrum Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.